As people with type 1 diabetes (insulin‐treated) are more prone to experience hypoglycaemia compared with non‐insulin‐treated, this could led to differential misclassification and may slightly affect HbA1c‐ and glucose‐lowering drug trends in the group characterized as likely type 2 diabetes patients. The gene discussed is INS; the disease is type 1 diabetes mellitus.